Baysient’s revolutionary iDose software calculates a precise, model-informed dose of medication to help patients reach, and stay in, remission. We understand that all patients are unique and deserve customized therapies to drive improved treatment outcomes. iDose works by calculating treatment plans that yield a significantly lower incidence of anti-drug antibodies and treatment failures to help patients reach remission faster and remain asymptomatic.
Currently, Infliximab is the only drug approved for precision dosing through iDose. However, Infliximab treats a variety of inflammatory diseases, making it a life-changing drug for millions of patients. Through iDose, Baysient can help improve the efficacy of Infliximab for the following conditions:
- Crohn’s disease
- Ulcerative colitis
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Plaque psoriasis
iDose is a cloud-based application that makes it easy for physicians to calculate the precise dose of medication needed to help patients experience improved treatment outcomes. Every inflammatory-disease patient is different and requires individualized dosing. With iDose, patients and physicians can feel confident in the treatment process.
As studies continue, more and more medications will become compatible with the iDose application. Physicians can get started with iDose today by scheduling their free demonstration. Patients can talk to their physician about acquiring iDose if they are interested in receiving quality, precision care.